Premium
Adiponectin induces the transforming growth factor decoy receptor BAMBI in human hepatocytes
Author(s) -
Wanninger Josef,
Neumeier Markus,
Bauer Sabrina,
Weiss Thomas S.,
Eisinger Kristina,
Walter Roland,
Dorn Christoph,
Hellerbrand Claus,
Schäffler Andreas,
Buechler Christa
Publication year - 2011
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/j.febslet.2011.04.003
Subject(s) - endocrinology , medicine , transforming growth factor , adiponectin , decoy , fibrosis , fatty liver , nonalcoholic fatty liver disease , transforming growth factor beta , connective tissue , chemistry , biology , receptor , cancer research , diabetes mellitus , insulin resistance , genetics , disease
Transforming growth factor (TGF) β is the central cytokine in fibrotic liver diseases. We analyzed whether hepatoprotective adiponectin directly interferes with TGFβ1 signaling in primary human hepatocytes (PHH). Adiponectin induces the TGFβ decoy receptor BMP‐and activin‐membrane‐bound inhibitor (BAMBI) in PHH. Overexpression of BAMBI in hepatoma cells impairs TGFβ‐mediated phosphorylation of SMAD2 and induction of connective tissue growth factor. BAMBI is lower in human fatty liver with a higher susceptibility to liver fibrosis and negatively correlates with BMI of the donors. Hepatic BAMBI is reduced in rodent models of liver inflammation and fibrosis. In summary, the current data show that hepatoprotective effects of adiponectin include induction of BAMBI which is reduced in human fatty liver and rodent models of metabolic liver injury.